简 体
繁 體
English
Research Platform
XW Labs has established two platforms, Prodrug Platform and Functional Group Switch (FGS) Platform, both of which allow for quick paths to identify novel candidates by potentially reducing the development cost/time to achieve clinical Proof of Concept.

The company intends to leverage its expertise and successful experience in pro-drug design and development to address issues associated with some existing drugs and compounds in development that lack optimal ADME properties for improved oral drugs. This approach provides unique opportunities to generate patentable composition and to develop new indication(s) while avoiding the high attrition rate in target validation and the HTS hit identification. Also when compared to its parent drug, pro-drugs with optimized ADME properties exhibit superior advantages leading to improved patients' compliance/convenience and/or lowered toxicity profile during drug treatment.

The company also established Functional Group Switch (FGS) platform that can potentially facilitate rapid identification of the second generation drug candidate, i.e. the best in class, for a group of existing drugs. This platform technology involves a switch of one specific functional group commonly found in some marketed drugs to another specific functional group that is not claimed by the drug's patent. Due to the nature of "switched" functional group, the new molecule is chemically more stable with a potentially superior pharmacokinetic (PK) profile (e.g., longer half-life) to the marketed drug while maintaining similar affinities to the targeted receptor.

Based on the above described platforms, we are also actively discussing with other pharmaceutical companies for collaborative opportunities on clinically studied compounds as well as marketed drugs in order to position ourselves to extend a sustainable pipeline for quick entry into commercial markets. 
Copyright 2015 XW Laboratories Inc. All rights reserved.